Headlines about Medovex Corp. (NASDAQ:MDVX) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medovex Corp. earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.6393151287217 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Medovex Corp. (NASDAQ MDVX) traded up 0.12% on Tuesday, reaching $1.18. The company’s stock had a trading volume of 30,324 shares. Medovex Corp. has a 52-week low of $1.00 and a 52-week high of $1.82. The stock’s market cap is $24.69 million. The firm’s 50-day moving average price is $1.18 and its 200-day moving average price is $1.21.
In other Medovex Corp. news, Director Steve Gorlin acquired 50,000 shares of the stock in a transaction dated Monday, August 21st. The stock was purchased at an average cost of $1.25 per share, with a total value of $62,500.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Over the last three months, insiders bought 290,989 shares of company stock valued at $279,700. Corporate insiders own 25.10% of the company’s stock.
Medovex Corp. Company Profile
MedoveX Corporation, through its subsidiaries, focuses on developing medical devices primarily in the United States and Europe. It offers DenerveX device, a disposable single-use kit for the treatment of various medical applications, including pain relief. The company serves healthcare providers, physicians, and third-party payors.
Receive News & Ratings for Medovex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medovex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.